Impact of age and SARS-CoV-2 breakthrough infection on humoral immune responses after

three doses of COVID-19 mRNA vaccine

Francis Mwimanzi[1], Hope R. Lapointe[2], Peter K. Cheung[1,2], Yurou Sang[1], Fatima Yaseen[1], Rebecca
Kalikawe[1], Sneha Datwani[1], Laura Burns[3], Landon Young[3], Victor Leung[4,5], Siobhan Ennis[1], Chanson
J. Brumme[2,4], Julio S.G. Montaner[2,4], Winnie Dong[2], Natalie Prystajecky[5,6], Christopher F. Lowe[3,5],
Mari L. DeMarco[3,5], Daniel T. Holmes[3,5], Janet Simons[3,5], Masahiro Niikura[1], Marc G. Romney[3,5,*],
Zabrina L. Brumme[1,2,*], Mark A. Brockman[1,2,*]
9
1. Faculty of Health Sciences, Simon Fraser University, Burnaby, V5A 1S6, Canada;
2. British Columbia Centre for Excellence in HIV/AIDS, Vancouver, V6Z 1Y6, Canada;
3. Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, V6Z 1Y6, Canada;
4. Department of Medicine, University of British Columbia, Vancouver, V6T 1Z3, Canada;
5. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver,
V6T 1Z7, Canada
6. British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, V5Z 4R4,
Canada
18
*MAB, MGR and ZLB contributed equally

Corresponding Author Contact Information:

Mark A. Brockman, Ph.D.

Professor, Faculty of Health Sciences, Simon Fraser University

8888 University Drive, Burnaby, BC, Canada, V5A 1S6

Tel: 778 782-3341; Fax: 778-782-5927;

email: mark_brockman@sfu.ca

ABSTRACT

Background

Longer-term immune response data after three doses of COVID-19 mRNA vaccine remain limited,

particularly among older adults and following Omicron breakthrough infection.

Methods

We quantified wild-type- and Omicron-specific serum IgG levels, ACE2 displacement activities and

live virus neutralization up to six months post-third dose in 116 adults aged 24-98 years who remained

COVID-19-naïve or experienced their first SARS-CoV-2 infection during this time.

Results

Among 78 participants who remained COVID-19-naïve throughout follow-up, wild-type- and Omicron

BA.1-specific IgG concentrations were comparable between younger and older adults, though BA.1-

specific responses were consistently significantly lower than wild-type-specific responses in both

groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates among COVID-19-

naïve younger and older adults, with median half-lives ranging from 69-78 days. Antiviral antibody

function declined substantially over time in COVID-19-naïve individuals, particularly older adults: by

six months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of

younger adults. SARS-CoV-2 infection, experienced by 38 participants, boosted IgG levels and

neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization

remained significantly lower than wild-type, with BA.5-specific neutralization lower still.

Conclusions

Our findings underscore the immune benefits of third COVID-19 mRNA vaccine doses in adults of all

ages, but rapid decline of Omicron-specific neutralization activity in COVID-19-naïve individuals,

particularly among older adults, demonstrates the need for fourth doses within 3-6 months to maintain

systemic responses. Individuals who experienced SARS-CoV-2 breakthrough infection post-third

vaccine dose however can likely delay a fourth dose beyond this timeframe.

Key words: COVID-19, mRNA vaccine, humoral immunity, hybrid immunity, post-vaccination

infection, older adults, binding antibodies, viral neutralization, Omicron

INTRODUCTION

Third COVID-19 mRNA vaccine doses have been provided to immunocompromised and clinically-vulnerable individuals to complete their initial vaccine series [1-3] and to the general population as "booster doses" to offset the natural decline of systemic antibodies [4, 5] and to augment responses against recent Omicron variants [6] that are more immune-evasive [7-14]. While third doses can enhance vaccine-induced protection against severe disease [1, 15, 16], they are not as effective to prevent Omicron-driven infections [17-19]. Few studies have assessed the durability of immune responses after three vaccine doses across the adult age spectrum, nor compared vaccine-induced responses to hybrid responses elicited in the now substantial number of individuals who experienced their first SARS-CoV-2 infection post-third vaccine dose, in one of the recent Omicron-driven waves. Longer-term monitoring of antibody responses and antiviral functions specific to both wild-type and Omicron variants among vaccinated individuals who remain COVID-19-naive versus those who experienced breakthrough Omicron infection can help inform the design, delivery and timing of additional COVID-19 vaccine doses.

In a prior study, we reported that older adults mounted weaker antibody responses than younger adults after two mRNA vaccine doses, but initial responses after three doses were equivalent between these groups [20]. Here, we longitudinally examine wild-type- and Omicron (BA.1, BA.2, BA.3 and BA.5)-specific antibody concentrations and/or antiviral function up to six months post-third dose in 116 individuals ranging in age from 24 to 98 years old who remained COVID-19-naïve until at least one month after receiving their third dose. While two-thirds of the cohort remained COVID-19-naïve throughout follow-up, one-third experienced their first SARS-CoV-2 infection during this time, presumably with Omicron BA.1 or BA.2, based on local molecular epidemiology trends during the study period [21]. This allowed us to additionally compare vaccine-induced and "hybrid" (combined

vaccine and infection-induced [22]) immune responses specific to wild-type and Omicron variants,

across age groups.

METHODS

Participants. Our cohort, based in British Columbia (BC) Canada, has been described previously [20].

Here, we studied the subset of 69 healthcare workers (HCW) and 47 older adults (OA) who remained

COVID-19 naive until at least one month after their third COVID-19 mRNA vaccine dose (**Table 1**).

SARS-CoV-2 infections were detected by the development of serum antibodies against Nucleocapsid

(N) using the Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with diagnostic (PCR-

and/or rapid-antigen-test-based) information where available.

Ethics approval. Written informed consent was obtained from all participants or their authorized

decision makers. This study was approved by the University of British Columbia/Providence Health

Care and Simon Fraser University Research Ethics Boards.

Assays. We quantified IgG-binding antibodies in serum against the SARS-CoV-2 Spike Receptor

Binding Domain (RBD) using the V-plex SARS-CoV-2 (IgG) ELISA kit (Panel 22; Meso Scale

Diagnostics), which features WT (Wuhan) and Omicron (BA.1) RBD antigens, on a Meso QuickPlex

SQ120 instrument. Serum was diluted 1:10000, with results reported in Arbitrary Units (AU)/mL. We

assessed surrogate virus neutralization activity [23] in serum by competition ELISA using the same kit

(Panel 22; V-plex SARS-CoV-2 [ACE2]) to measure blockade of the RBD-ACE2 receptor interaction.

Sera were diluted 1:40 and results reported as the percentage (%) ACE2 displacement. A subset of

specimens was also tested for IgG-binding antibodies and ACE2 displacement using V-plex ELISA

kits that featured Wuhan, BA.1, BA.2 and BA.3 Spike antigens (Panel 25; Meso Scale Diagnostics).

Virus neutralizing activity in plasma was examined using live wild-type (WT) (USA-WA1/2020; BEI

Resources), Omicron BA.1 (GISAID EPI_ISL_9805779) and Omicron BA.5 (GISAID

EPI_ISL_15226696) SARS-CoV-2 strains on VeroE6-TMPRSS2 (JCRB-1819) target cells [20]. Virus

stocks were diluted to 50 $TCID_{50}$/200 µl in the presence of serial 2-fold plasma dilutions (1/20 to

1/2560) and added to target cells in triplicate. Viral cytopathic effect (CPE) was recorded three days

post-infection. Neutralization was reported as the highest reciprocal dilution able to prevent CPE in all

three wells. Partial or no neutralization at 1/20 dilution was considered below the limit of quantification

(BLOQ).

RESULTS

Participant characteristics

HCW and OA were a median of 40 and 78 years old, respectively (overall range 24-98 years

old), and predominantly female (**Table 1**). OA were predominantly of white ethnicity (74%, compared

to 46% of HCW) and had more chronic health conditions (median of 1, interquartile range [IQR] 0-2 in

OA versus 0 [IQR 0-1] in HCW). Most participants (97% of HCW and 81% of OA) initially received

two doses of BNT162b2; the remainder received two doses of mRNA-1273 or a heterologous mRNA

vaccine regimen. Third doses were predominantly mRNA-1273 (52% of HCW and 62% of OA), which

were administered in an age-dependent manner per local guidelines: most OA received 100 mcg

whereas HCW received 50 mcg. Third doses were administered an average of ~7 months after the

second dose. During follow-up, 43% of HCW and 17% of OA experienced their first SARS-CoV-2

infection, the vast majority of which were likely Omicron BA.1 or BA.2, based on local molecular

epidemiology trends during the study period [21].

Binding antibody responses after vaccination and breakthrough Omicron infection

As reported previously [20, 24], anti-RBD serum IgG concentrations specific to both WT and Omicron BA.1 were significantly lower in COVID-19-naïve OA compared to younger HCW after two vaccine doses, but the third dose substantially enhanced IgG responses in both groups, such that they reached equivalence at one month post-third-dose (**Figure 1A**). At this time point for example, WT-specific anti-RBD IgG concentrations were a median of 5.21 (IQR 5.08-5.45) $\log_{10}$ AU/mL in HCW versus 5.25 (IQR 4.99-5.43) $\log_{10}$ AU/mL in OA (p=0.7). Among the participants who remained COVID-19-naive throughout follow-up, WT-specific IgG responses declined to a median 4.95 (IQR 4.79-5.16) $\log_{10}$ AU/mL in HCW versus 4.96 (IQR 4.76-5.17) $\log_{10}$ AU/mL in OA at three months post-third dose, levels that were not significantly different between groups (p=0.9). By six months post-third dose, WT-specific IgG responses had declined to a median 4.64 (IQR 4.42-4.84) $\log_{10}$ AU/mL in HCW versus 4.59 (IQR 4.35-4.87) $\log_{10}$ AU/mL, levels that were again not significantly different between groups (p=0.7). Nevertheless, the magnitude of these declines meant that WT-specific IgG concentrations in COVID-19-naïve HCW had declined to significantly below peak post-second-dose levels by six months after the third dose, (p<0.0001), while in OA they had declined to comparable levels as those elicited by two doses (p=0.2). Identical trends were observed for BA.1-specific IgG among COVID-19-naïve HCW and OA, though these were on average ~0.6 $\log_{10}$ AU/mL lower than WT-specific responses at all time points, differences that were statistically significant at p<0.0001 in all cases (though these comparisons are not shown in Figure 1A to minimize clutter).

By contrast, individuals who experienced their first SARS-CoV-2 infection at some time between one and six months following their third vaccine dose exhibited markedly higher virus-specific IgG concentrations than their COVID-19-naïve counterparts at both three and six months post-

third dose (all comparisons p<0.001 for both WT- and BA.1-specific responses; **Figure 1A**).

Moreover, stratifying the hybrid immune responses by participant age group revealed that older adults

who contracted SARS-CoV-2 mounted equivalent or higher WT-specific IgG responses compared to

younger HCW at all time points studied (p-values ranging from 0.01 to 0.8), and equivalent BA.1-

specific IgG responses compared to HCW (p-values ranging from 0.1-0.9) (**Figure 1B**). In fact, at six

months post-third-dose, both WT- and BA.1-specific IgG concentrations among the hybrid immune

participants of all ages were significantly higher than their original peak responses induced by three

vaccine doses alone: at six months the median WT-specific IgG concentration was 5.50 (IQR 5.17-

5.79) $\log_{10}$ AU/mL in the combined hybrid group, which was ~0.25 $\log_{10}$ AU/mL higher than that

observed at one month post-third dose (p=0.0005). Visualizing the data in terms of individual-level

longitudinal responses revealed that, while most individuals enjoyed a substantial boost in terms of

both WT- and BA.1-specific responses following SARS-CoV-2 infection, responses in a minority of

participants remained constant or even declined thereafter (**Figure 1B).**

Our longitudinal data also allowed us to estimate the half-lives of wild-type and BA.1-specific

IgG concentrations in serum among individuals who remained COVID-19 naive over the subsequent

six months. Following three vaccine doses, the half-life of WT-specific IgG was estimated to be a

median 73 (IQR 53-101) days in COVID-19-naïve HCW versus 69 (IQR 54-91) days in OA, a

difference that was not statistically significant (p=0.8; **Figure S1A, B**). In COVID-19-naïve

individuals, BA.1-specific IgG half-lives were similar to those for WT and were also comparable

between OA (median 75 days [IQR 58-93]) and HCW (78 [IQR 64-94]) (p=0.5; **Figure S1C, D**).

ACE2 displacement activity after vaccination and breakthrough Omicron infection

As reported previously [20, 24], the antiviral function of antibodies measured by ACE2

displacement activity against WT and the Omicron BA.1 variant was lower in COVID-19-naïve OA

compared to HCW following two vaccine doses, but these responses increased to equivalence one

month after the third dose. Specifically, these responses reached a median 98.7% (IQR 96.3-99.3) in

HCW versus 99.3% (IQR 96.0-99.7) OA for WT (p=0.12), and a median of 62.5% (IQR 46.2-75.5) in

HCW versus 66.2% (IQR 44.6-79.3) in OA for BA.1 (p=0.4) (**Figure 2A**). Among the participants who

remained COVID-19-naive throughout follow-up, WT-specific ACE2 displacement activities declined

similarly in both groups, to a median 98.0% (IQR 93.7-99.3) in HCW versus 98.3% (IQR 91.7-99.5) in

OA at three months after the third dose (p=0.9) and a median 92.8% (IQR 80.0-99.9) in HCW versus

91.4% (IQR 72.3-97.1) in OA at six months (p=0.4). Somewhat in contrast, BA.1-specific ACE2

displacement activity declined slightly faster in COVID-19-naïve OA compared to HCW, particularly

between three and six months after the third dose. Specifically, BA.1-specific ACE2 displacement

activities had declined to a median 48.6% (IQR 20.5-73.8) in HCW versus 47.6% (IQR 14.2-71.7) in

OA at three months (p=0.4) and to a median 43.3% (IQR 13.4-62.2) in HCW versus 20.7% (IQR 5.6-

32.3) in OA at six months (p=0.04). Similar to the declines observed in IgG concentrations over time,

by six months post-third dose, WT- and BA.1-specific ACE2 displacement activities in COVID-19-

naïve HCW had declined to below the peak levels elicited after only two vaccine doses (p<0.0001 and

p=0.02 respectively), while in COVID-19-naïve OA they had declined to comparable levels as

achieved after two doses (p=0.6 and p=0.4, respectively).

By contrast, individuals who experienced their first SARS-CoV-2 infection between one and six

months following their third vaccine dose showed a strong boost in ACE2 displacement activity at both

three and six months, where this difference was most apparent for the BA.1-specific responses (all

comparisons p<0.0001 for both WT and BA.1; **Figure 2A**). In fact, at six months after the third dose,

both WT- and BA.1-specific ACE2 displacement activities in the hybrid immune group significantly

exceeded those induced by vaccination alone (both comparisons p<0.0001; **Figure 2A**). For example,

BA.1-specific ACE2 displacement activities rose to a median 95.9% (IQR 90.0-97.8) in the hybrid

group at six months, levels that were an average 30% higher than those induced by three-dose

vaccination alone. Similar to the results observed for IgG concentrations, stratifying the hybrid immune

responses by participant age group revealed that older adults who contracted SARS-CoV-2 exhibited

equivalent or higher WT-specific ACE2 displacement activities compared to younger HCW at all time

points studied (p-values ranging from 0.006 to 0.9), and equivalent BA.1-specific ACE2 displacement

activities compared to HCW (p-values ranging from 0.4-0.9) (**Figure 2B**). Also similar to the IgG

observations, visualizing the ACE2 displacement results in terms of individual-level longitudinal

responses revealed that SARS-CoV-2 infection enhanced both WT- and Omicron BA.1-specific ACE2

displacement activities in most, but not all, individuals (**Figure 2B).**

Virus neutralization activity after vaccination and breakthrough Omicron infection

As reported previously [20, 24], live virus neutralization activities against both the WT and

Omicron BA.1 variants were weaker in OA compared to younger HCW following two vaccine doses,

but these activities were enhanced and reached equivalence one month after the third dose (**Figure 3A**).

Specifically, at this time point, the reciprocal plasma dilutions required to neutralize WT were a median

320 (IQR 160-320) in HCW versus a median 320 (IQR 80-640) in OA (p=0.9), while those required to

neutralize BA.1 were a median 40 (IQR 20-80) in both groups (p=0.8). Among the participants who

remained COVID-19-naïve throughout follow-up, WT neutralization activity declined relatively

similarly in both groups, to median reciprocal dilutions of 80 (IQR 80-160) in HCW versus 80 (IQR

40-160) in OA at three months post-third dose (p=0.03), and a median 40 (IQR 20-80) in HCW versus

20 (IQR 20-80) in OA at six months (p=0.3). Nevertheless, by six months, WT-specific neutralization

activities in COVID-19-naïve HCW and OA had declined to below the peak levels induced by two

vaccine doses (p<0.0001 in HCW and p=0.045 in OA; **Figure 3A**). Moreover, BA.1-specific

neutralization activity declined faster in COVID-19-naïve OA compared to HCW after three vaccine

doses. Specifically, at three months post-third-dose, BA.1-specific neutralization in HCW had declined

to a median reciprocal dilution of 20 (IQR 20-40), whereas in 79% of OA this function was below the

limit of quantification (BLOQ) (p=0.004). By six months, BA.1-specific-neutralization activity had

declined to BLOQ in 56% and 96% of COVID-19-naive HCW and OA respectively (p=0.003),

activities that were lower than peak responses induced by two vaccine doses (p=0.02 for HCW; p=0.06

for OA).

By contrast, individuals who experienced their first SARS-CoV-2 infection between one and six

months following their third vaccine dose showed a strong enhancement in their ability to neutralize

both WT and BA.1 (all comparisons p<0.0001; **Figure 3A**). At six months, participants in the hybrid

immune group displayed significantly higher WT- and BA.1-specific neutralization activities compared

to peak responses induced by three vaccine doses alone (all p≤0.002; **Figure 3A**): at this time point

BA.1-specific neutralization in the hybrid immune group was achieved with a median reciprocal

dilution of 80 (IQR 80-160), compared to a median 40 (IQR 20-80) observed in the combined HCW

and OA group at one month following the third vaccine dose.

Similar to observations made for other humoral responses, stratifying the hybrid immune

responses by age indicated that OA exhibited equivalent WT- and BA.1-specific neutralization

activities compared to younger HCW at all time points (p-values ranging from 0.3 to 0.9) (**Figure 4B**).

Furthermore, visualization of individual-level longitudinal responses revealed that while SARS-CoV-2

infection boosted both WT- and BA.1-specific neutralization activities in most individuals, some

individuals' responses remained stable or declined following infection (**Figure 4B**).

Responses to newer Omicron variants, including BA.5

While the BA.1 variant drove the first global wave of Omicron infections, this strain has largely

been replaced by newer Omicron variants that demonstrate distinct abilities to evade neutralizing

antibodies [8, 25-29]. To begin to evaluate vaccine and hybrid immune responses to other Omicron

strains, we quantified anti-Spike IgG and ACE2 displacement activities specific to WT, BA.1, BA.2

and BA.3 variants in a subset of 25 COVID-19 naïve participants at one month after their third vaccine

dose (**Figure S2**). Compared to WT-specific responses, anti-Spike IgG concentrations were on average

~0.4 $\log_{10}$ AU/mL lower for each of these Omicron variants, while ACE2 displacement activities were

on average at least 30% lower for these Omicron variants (all $p<0.0001$; **Figure S2**). BA.2-specific

anti-Spike IgG concentrations were comparable to BA.1 ($p=0.2$), while BA.2-specific ACE2

displacement activities were marginally lower ($p=0.01$). BA.3-specific anti-Spike IgG concentrations

and ACE2 displacement activities were significantly lower than those against BA.1 (both $p<0.0001$),

though the magnitude of these differences was modest (*e.g.* median IgG was 5.42 $\log_{10}$ AU/mL for

BA.1 versus 5.35 $\log_{10}$ AU/mL for BA.3). The correlation between the present anti-Spike and the

original anti-RBD measurements for the WT and BA.1 antigens (shown in Figure 1) was strong

(Spearman's $\rho \geq 0.86$, $p<0.0001$; **Figure S2**).

Omicron BA.5 emerged in early 2022 [30] and is currently the dominant SARS-CoV-2 variant

circulating globally [31-34]. To investigate vaccine- and hybrid-induced immune responses against this

strain, we performed live virus neutralization assays using a local BA.5 isolate in a subset of 36

participants (28 HCW and 8 OA) who experienced SARS-CoV-2 breakthrough infection between one

and six months after receiving three vaccine doses (**Figure 4**). For each individual, vaccine-induced

neutralization activity was tested at one-month post-third dose, and hybrid-induced neutralization

activity was tested following SARS-CoV-2 anti-N seroconversion (either three months or six months

post-third vaccine dose). Based on local molecular epidemiology reports [21], SARS-CoV-2 infections

among these participants were likely due to BA.1 or BA.2 (not BA.5). Neutralization results for BA.5

were compared to those against WT and BA.1 at the same timepoints (*i.e.* the data from Figure 4).

Consistent with recent reports showing that BA.5 is more immune-evasive than prior Omicron variants

[26-28], we observed that neutralization activity against BA.5 was significantly lower than activities

against WT and BA.1 following three vaccine doses ($p<0.0001$ and $p=0.015$, respectively) (**Figure**

4A). Indeed, the median reciprocal dilution for BA.5 neutralization was 20 (IQR BLOQ-20) at this time

point. Neutralization activity against all three virus strains was enhanced significantly following

infection (all $p≤0.0003$) (**Figure 4B**), but the hybrid immune response against BA.5 (median reciprocal

dilution 80, IQR 40-160) nevertheless remained significantly lower than that against both WT

($p<0.0001$) and BA.1 ($p=0.0014$) (**Figure 4A**). Overall, no significant difference in BA.5 neutralization

activity was found between OA and younger HCW at either one month post-third vaccine dose nor

after acquiring hybrid immunity (**Figure 4B**).

DISCUSSION

Our observations confirm that a third COVID-19 mRNA vaccine dose significantly enhances

antibody responses against both WT and Omicron variants in COVID-19-naïve individuals, particularly

among older adults. Our results also shed light on the durability of these responses, revealing that WT-

and Omicron BA.1-specific anti-RBD binding IgG concentrations remained comparable in magnitude

and declined at similar rates in older and younger adults in the six months following the third dose,

though BA.1-specific responses were consistently ~0.6 $\log_{10}$ AU/mL lower than those against WT. By

contrast, antiviral antibody functions, particularly those specific to Omicron, declined substantially in

all participants who remained COVID-19-naïve over the study period, and especially so in older adults.

By six months post-third-dose, antibody responses in COVID-19-naïve participants of all ages had

declined markedly to or below the peak levels elicited by two vaccine doses, and BA.1-specific

neutralization activity had declined to below the limit of quantification in 56% of younger adults and

96% of older adults. In fact, BA.1-specific neutralization activity had already declined to below the

limit of quantification in 79% of COVID-19-naïve older adults by three months after the third dose.

These observations, along with the finding that ACE2 displacement function declined more rapidly in

COVID-19 naive older adults, suggest that Omicron-specific antibody function may be impaired in

older age, but where this impairment is only revealed as antibody concentrations decline.

By contrast, both younger and older adults who experienced their first SARS-CoV-2 infection

(presumably Omicron BA.1 or BA.2 [21]) after receiving three vaccine doses demonstrated superior

binding antibody concentrations and functional responses, including against the heterologous Omicron

variant BA.5, compared to those induced by three vaccine doses alone, though the ability to neutralize

BA.5 remained significantly poorer than the ability to neutralize BA.1 even after infection.

Nevertheless, and importantly, the magnitude of humoral responses following acquisition of hybrid

immunity did not differ significantly between older and younger adults (though the modest number of

older adults with hybrid immunity should be acknowledged). These results are consistent with other

studies of hybrid immunity [22, 35, 36] and suggest that a post-third-dose Omicron infection will

prolong immune protection against Omicron strains for at least a short period. The observation that

viral infection led to a pronounced enhancement of Omicron-specific responses, including binding

antibody concentration and virus neutralization activity, is likely attributable to exposure to Omicron

Spike. If so, bivalent vaccines that include variant Omicron Spike antigens may offer similar

advantages, including the ability to elicit superior immune responses against circulating variants

compared to existing WT-only vaccines. Intriguingly, while most participants displayed a significant

boost in humoral responses following virus infection (and will potentially benefit from hybrid

immunity), this did not occur in all cases. Additional research will be necessary to investigate the

factors that contribute to such divergent outcomes.

CONCLUSSIONS

In conclusion, this study underscores the immune benefits of third/booster COVID-19 vaccine

doses in all ages. The results also suggest that younger adults who have received three COVID-19

vaccine doses but who have not yet experienced a SARS-CoV-2 infection will require an additional

vaccine dose within six months to maintain systemic antibody responses, while SARS-CoV-2-naïve

older adults may benefit from an additional vaccine dose within as few as three months. By contrast,

individuals who experienced SARS-CoV-2 breakthrough infection after receiving three vaccine doses

can likely delay a fourth dose beyond this time frame. Additional studies are needed to assess the

durability of hybrid immune responses and to evaluate cross-reactivity against emerging SARS-CoV-2

variants, particularly in the context of bivalent vaccines that incorporate Omicron Spike antigen.

AUTHOR CONTRIBUTIONS

MGR, ZLB and MAB led the study. HRL coordinated the study. FM, PKC, YS, FY, LB, SE and WD collected data under the supervision of MLD, VL, JSGM, DTH, JS, MGR, ZLB and MAB. FM, HL, MAB and ZLB analyzed data. YS curated the specimen repository. LY performed phlebotomy and assisted with logistics. FM, YS, RK and SD processed specimens and curated data. CJB advised on data analysis. NP provided data. CFL provided specimens. MN isolated SARS-CoV-2. ZLB and MAB wrote the manuscript. All authors contributed to manuscript review and editing.

ACKNOWLEDGEMENTS

We thank the leadership and staff of Providence Health Care, including long-term care and assisted living residences, for their support of this study. We thank the phlebotomists and laboratory staff at St. Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and Innovation Centre, and Simon Fraser University for assistance. Above all, we thank the participants, without whom this study would not have been possible.

FUNDING

This work was supported by the Public Health Agency of Canada through a COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120 to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for Health Research (GA2-177713 and the Coronavirus Variants Rapid Response Network (FRN-175622) to MAB), the Canada Foundation for Innovation through Exceptional Opportunities Fund – COVID-19 awards (to MAB, MD, MN, ZLB). FM is supported by a fellowship from the CIHR Canadian HIV Trials Network. FY was

supported by an SFU Undergraduate Research Award. MLD and ZLB hold Scholar Awards from the

Michael Smith Foundation for Health Research.

FIGURE LEGENDS

Figure 1. WT- and Omicron BA.1-specific anti-RBD IgG concentrations following three-dose

COVID-19 vaccination. *Panel A:* Longitudinal serum anti-RBD IgG concentrations specific to WT

(left side) and Omicron BA.1 (right side) in COVID-19-naive health care workers (HCW; blue circles)

and older adults (OA; orange circles). Any participant who experienced a SARS-CoV-2 breakthrough

infection between 1-3 or 3-6 months post-third-dose was reclassified into the "hybrid" group at their

following study visit, with HCW in blue and OA in orange circles. At six months post-third-dose, the

darker-colored symbols in the hybrid group denote recent infections that occurred between 3-6 months,

while the lighter-colored symbols denote the infections that had previously occurred between 1-3

months. Red bars indicate median and IQR. Comparisons between independent groups were performed

using the Mann-Whitney U-test; longitudinal paired comparisons were performed using the Wilcoxon

matched pairs test. P-values are not corrected for multiple comparisons. *Panel B:* Same data as panel

A, but where serum anti-RBD IgG concentrations are plotted longitudinally by participant (HCW in

blue, OA in orange). Participants are stratified into three groups: those who remained COVID-19 naive

throughout the study, those who acquired SARS-CoV-2 between 1-3 months post-third-dose, those

who acquired SARS-CoV-2 between 3-6 months post-third-dose. Horizontal red lines denote the

overall median response at each time point, where HCW and OA are treated as a combined group. P-

values on top of larger brackets compare responses between time points using the Wilcoxon matched

pairs test, where HCW and OA are treated as a combined group. P-values on top of small brackets

compare responses between HCW and OA at each time-point post SARS-CoV-2 infection using the

Mann-Whitney U test. P-values are not corrected for multiple comparisons.

Figure 2. WT- and Omicron BA.1-specific ACE2% displacement function following three-dose

COVID-19 vaccination. *Panel A:* Same as Figure 1A, but for ACE2 displacement activity in serum, a

surrogate measure of virus neutralization, where results are reported in terms of % ACE2 displacement.

Panel B: Same data as panel A, but where ACE2 % displacement activities are plotted longitudinally

by participant (HCW in blue, OA in orange). The legend is the same as for Figure 1B.

Figure 3. WT- and Omicron BA.1-specific live virus neutralization activity following three-dose

COVID-19 vaccination. *Panel A:* Same as Figure 1A, but for live virus neutralization activity, defined

as the lowest reciprocal plasma dilution at which neutralization was observed in all wells of a triplicate

assay. Serial two-fold dilutions of 1/20 (lower limit of quantification; LLOQ) to 1/2560 (upper limit of

quantification; ULOQ) were tested. Plasma samples showing neutralization in fewer than three wells at

a 1/20 dilution are displayed as a reciprocal dilution of "10" and were reported as below limit of

quantification (BLOQ) in the text. Omicron-BA.1 specific neutralization was performed on a subset of

samples only. *Panel B:* Same data as panel A, but where neutralization activities are plotted

longitudinally by participant (HCW in blue, OA in orange). The legend is the same as for Figure 1B.

Note that many datapoints are superimposed in both panels.

Figure 4. WT-, Omicron BA.1- and Omicron BA.5-specific live virus neutralization activity

before and after attainment of hybrid immunity. *Panel A:* WT-, Omicron BA.1- and Omicron

BA.5-specific neutralization activities in 28 HCW (blue circles) and 8 OA (orange circles) one month

after the 3rd vaccine dose ("vaccine only") and after subsequent SARS-CoV-2 infection ("hybrid"). In

this panel, data are plotted to facilitate comparisons between neutralization activities to the three

SARS-CoV-2 variants, before and after attainment of hybrid immunity. P-values, computed on

combined HCW and OA as a combined group, were computed using the Wilcoxon matched pairs test.

P-values are not corrected for multiple comparisons. ULOQ/LLOQ: upper/lower limit of

quantification. *Panel B*: Same data as in panel A, but plotted longitudinally by participant, and

stratified by SARS-CoV-2 variant, to highlight the change in neutralization activity before and after

attainment of hybrid immunity. Red lines indicate medians of HCW and OA treated as a combined

group. P-values on top of large brackets compare responses before and after hybrid immunity using the

Wilcoxon matched pairs test. P-values on top of small brackets compare responses between HCW and

OA at a given time point using the Mann-Whitney U test. Note that a large number of points are

superimposed in this plot.

Supplemental Figures

Figure S1: Temporal declines in WT- and Omicron BA.1-specific anti-RBD IgG decline following

three-dose COVID-19 vaccination. *Panel A:* Temporal declines in WT-specific anti-RBD IgG

responses following three-dose vaccination in HCW (blue) and OA (orange) who remained COVID-

19-naive during follow-up, and who completed all three post-third dose visits. *Panel B*: Estimated WT-

specific IgG half-lives following three-dose vaccination, calculated by fitting an exponential curve to

each participant's data in panel B. Red bars and whiskers represent the median and IQR. P-values were

computed using the Mann-Whitney U-test. *Panel C*: Same as panel A, but for Omicron (BA.1)-specific

anti-RBD IgG responses. *Panel D*: Same as panel B, but calculated from the Omicron (BA.1)-specific

anti-RBD IgG response data.

Figure S2: Anti-S IgG and ACE2 displacement activities against additional Omicron variants.

Panel A: Concentrations of IgG capable of binding WT, Omicron BA.1, BA.2 and BA.3 Spike proteins

in a subset of n=25 participants measured one month post-third vaccine dose. HCW in blue; OA in

orange; dots are jittered for visualization. P-values are computed using the Wilcoxon matched pairs test

and are uncorrected for multiple comparisons. Horizontal red lines denote the overall median response

to each variant (HCW and OA are treated as a combined group). *Panel B*: same as Panel A, but for

ACE2% displacement activity. *Panel C*: Correlation between WT and Omicron BA.1-specific anti-

Spike IgG concentrations (shown in this figure) with the original anti-RBD IgG measurements shown

in the primary analysis (in Figure 1A). *Panel D*: Correlation between WT and Omicron BA.1-specific

anti-Spike ACE2 displacement with the original anti-RBD measurements shown in the primary

analysis.

REFERENCES

1. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet **2021**; 398:2093-100.

2. Moreira ED, Jr., Kitchin N, Xu X, et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med **2022**; 386:1910-21.

3. Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A, et al. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >/=60 Years. JAMA **2021**; 326:2203-4.

4. Khoury J, Najjar-Debbiny R, Hanna A, et al. COVID-19 vaccine - Long term immune decline and breakthrough infections. Vaccine **2021**; 39:6984-9.

5. Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect **2021**; 10:1495-8.

6. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature **2022**; 603:679-86.

7. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature **2022**.

8. Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature **2022**; 608:603-8.

9. Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science **2022**; 375:760-4.

10. Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature **2022**; 602:657-63.

11. Hoffmann M, Kruger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell **2022**; 185:447-56 e11.

12. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell **2022**; 185:467-84 e15.

13. Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature **2022**; 602:671-5.

14. Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature **2022**; 602:676-81.

15. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N Engl J Med **2022**; 386:1804-16.

16. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
(B.1.1.529) Variant. N Engl J Med **2022**; 386:1532-46.

17. Christensen PA, Olsen RJ, Long SW, et al. Signals of Significantly Increased Vaccine
Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus
Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in
Houston, Texas. Am J Pathol **2022**; 192:642-52.

18. Staerke NB, Reekie J, Nielsen H, et al. Levels of SARS-CoV-2 antibodies among fully vaccinated
individuals with Delta or Omicron variant breakthrough infections. Nat Commun **2022**; 13:4466.

19. Gram MA, Emborg HD, Schelde AB, et al. Vaccine effectiveness against SARS-CoV-2 infection
or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide
Danish cohort study. PLoS Med **2022**; 19:e1003992.

20. Mwimanzi F, Lapointe HR, Cheung PK, et al. Older adults mount less durable humoral responses
to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose. J Infect Dis
2022.

21. BC Centre for Disease Control. Weekly update on Variants of Concern. Available at:
http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data. 2022.

22. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads
to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol **2022**;
7:eabn8014.

23. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on
antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol **2020**; 38:1073-
8.

24. Brockman MA, Mwimanzi F, Lapointe HR, et al. Reduced Magnitude and Durability of Humoral
Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. J Infect Dis **2022**; 225:1129-
40.

25. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron
BA.4 and BA.5 from vaccine and BA.1 serum. Cell **2022**; 185:2422-33 e13.

26. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron
infection. Nature **2022**; 608:593-602.

27. Khan K, Karim F, Ganga Y, et al. Omicron BA.4/BA.5 escape neutralizing immunity elicited by
BA.1 infection. Nat Commun **2022**; 13:4686.

28. Aggarwal A, Akerman A, Milogiannakis V, et al. SARS-CoV-2 Omicron BA.5: Evolving tropism
and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral
variants of concern. EBioMedicine **2022**; 84:104270.

29. Gruell H, Vanshylla K, Korenkov M, et al. SARS-CoV-2 Omicron sublineages exhibit distinct
antibody escape patterns. Cell Host Microbe **2022**; 30:1231-41 e6.

30. Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5
in South Africa. Nat Med **2022**; 28:1785-90.

31. European Centre for Disease Control. Situation updates on COVID-19: SARS-CoV-2 variants of
concern. Available at: https://www.ecdc.europa.eu/en/covid-19/variants-concern. Accessed 1 October
2022.

32. Government of Canada. COVID-19 epidemiology update. Available at: https://health-
infobase.canada.ca/covid-19/. Accessed 1 October 2022.

33. Centers for Disease Control and Prevention U. COVID Data Tracker: Variant Proportions.
Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed 1 October 2022.

34. World Health Organization. Coronavirus Update 80: What we know about new COVID-19
Variants of Concern. EPI-WIN Updates, **2022**.

35. Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to
SARS-CoV-2 variants. Sci Immunol **2022**:eabp8328.

36. Curlin ME, Bates TA, Guzman G, et al. Omicron neutralizing antibody response following booster
vaccination compared with breakthrough infection. medRxiv **2022**.
519

Table 1: Participant characteristics

Characteristic	HCW (n=69)	Older Adults (n=47)
Sociodemographic and health variables		
Age in years, median [IQR]	40 [34-51]	78 [72-83]
Female sex at birth, n (%)	53 (77%)	34 (72%)
white Ethnicity, n (%)	32 (46%)	35 (74%)
Number of chronic health conditions, median [IQR]	0 [0-1]	1 [0-2]
Vaccine details		
Initial regimen		
BNT162b2 - BNT162b2	67 (97%)	38 (81%)
mRNA-1273 - mRNA-1273	1 (1.5%)	7 (15%)
heterologous mRNA	1 (1.5%)	2 (4%)
Third dose		
BNT162b2	33 (48%)	18 (38%)
mRNA-1273	36 (52%)	29 (62%)
Date range that third doses were received	Oct 2021-Feb 2022	Oct 2021-Jan 2022
Time between second and third doses in days, median [IQR]	210 [199-232]	198 [173-216]
Specimen collection		
1 month after third dose, n (%)	68 (99%)	47 (100%)
3 months after third dose, n (%)	68 (99%)	45 (96%)
6 months after third dose, n (%)	57 (83%)	44 (94%)
Post-vaccination SARS-CoV-2 infections, n (%)	30 (43%)	8 (17%)

Figure 1

Figure 2

Figure 3